Clinical Trial Update: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the safety, immunogenicity, and preliminary clinical activity of the PDC*lung01 Cancer Vaccine in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PDC*lung01 Cancer Vaccine

Snippet

Sponsor: PDC*line Pharma SAS | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING